septerna - Search News

News

Novo Nordisk Inks $2.2B Deal With Septerna

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Reuters on MSN · 1d

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

Contract Pharma · 9h

Novo Nordisk Invests $2.2B in Septerna’s Oral Drugs

Septerna, Novo Nordisk partner to discover, develop and commercialize oral small molecule medicines for cardiometabolic diseases.

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

STAT1d

First patient treated with prime editing

From my colleague Jason Mast: The first ever patient has been treated with prime editing, a powerful technology for making ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Novo Nordisk Inks $2.2B Deal With Septerna

Trending now